Table 1 Previously proposed prognostic biomarkers in HNSCC 1
Biomarker2 | Clinical outcome | Method of detection | N. of cases/%/type of modulation | Annotation |
|---|---|---|---|---|
ADAM17 | Lymph nodal metastasis/Loco-regional relapse | IHC/WB | 50/46/Up | None |
CD44 | OS/DFS | IHC | 138/59/Down | None |
E-cadherin | Recurrence/OS | IHC | 50/20/Up 112/59/Down | None |
EGFR | OS | IHC | 109/73/Up 59/58/Up | None |
Estrogen-R2 | OS | IHC/nPCR + sequencing | 67/51/Up | Laryngeal/hypopharingeal cancer |
FHIT | OS/DFS | IHC | 53/61/Down | None |
GLUT1 | OS | IHC | 40/26/up | Poor radiation response |
HIF1A | OS/DFS | IHC | 85/63/Down | None |
Keratin-18 | OS | IHC | 308/54/Up | None |
Keratin-8 | OS | IHC | 308/54/Up | None |
Laminin γ2 | DSS | DNA Microarray | 119/NS/Up | None |
MCM5 | OS | IHC | 97/61/Up | None |
MET | OS | IHC | 69/82/Up | None |
Moesin | OS | IHC | 103/NS/Up | Cytoplasmic expression pattern |
Mucin-1 | OS/DFS/Lymphnodal metastasis | IHC | 206/39/Up | Within 5-years follow-up |
Mucin-4 | OS/DFS/Lymphnodal metastasis/Loco-regional relapse | IHC | 150/41/Up | Within 5-years follow-up |
p21 | OS | IHC | 192/71/Down | None |
p27 | DFS | IHC | 192/80/Down | Only in patients with lymphnodal infiltration |
p57 | OS | IHC | 67/87/Down | None |
p63 | OS | IHC | 62/NS/Up | None |
P-cadherin | Disease recurrence/Loco-regional relapse/OS | IHC | 50/20/Down 67/45/Down 108/16/Down | None |
Podoplanin | DSS | IHC | 35/56/Up | None |
Rb | DFS | IHC | 220/49/Down | Only in p53+/pRb− patients |
RUNX3 | OS | IHC/WB | 108/46/Down | None |
S100A2 | DFS/Cervical metastasis | RT-PCR + seq/IHC | 135/26/Down 52/NS/Down | Nuclear expression pattern |
SPARC | OS/DFI | DNA Microarray/IHC | 62/NS/Up | None |
STAT1 | OS | IHC | 89/NS/Up | None |
Survivin 3α | OS | RT-PCR | 97/NS/Up | Only in lymphnodes |
TERT | OS | IHC | 62/NS/Up | None |
Ezrin | OS | IHC | 47/85/Up | Cytoplasmic expression pattern |